

# PROJECT LIVIN' LABEL

LABELING UNFOLDED - KNOWLEDGE RELEASED

**AACR** American Association  
for Cancer Research\*

**FDA** U.S. FOOD & DRUG  
ADMINISTRATION



## Project Livin' Label Speaker Biographies

### Episode 5 – Venetoclax: The Backstory

---

#### Claude Sipe, *Patient*



Claude Sipe was diagnosed in 2017 with acute myeloid leukemia (AML), which progressed from myelodysplastic syndrome originally diagnosed in 2000. Mr. Sipe was enrolled in the clinical trial examining the efficacy of venetoclax plus azacytidine for AML. He is currently in remission.

Mr. Sipe grew up in Sonora, California, and currently resides in Camino with his wife of over 35 years. A square dancer since the age of 10, he has decades of experience as a square dance caller across North America and is a founder of the Apple Jacks 'n' Jills Square Dancing Club. He also enjoys making frequent fishing trips to Utah with his wife.

#### Courtney DiNardo, MD, *MD Anderson Cancer Center*



Dr. DiNardo is an academic clinical researcher with a primary focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups. Dr. DiNardo has experience in designing, overseeing, and executing successful clinical trials; from Phase 1 dose-finding studies to innovative investigator-initiated Phase II trials, to confirmatory randomized Phase III trials. Dr. DiNardo has served an integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, which have led to the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).

#### Jalaja Potluri, MD, FACP, *AbbVie*



Dr. Jalaja Potluri is an Executive Medical Director at AbbVie and the Development Leader for VENCLEXTA (venetoclax) in myeloid malignancies. Dr. Potluri is a hematologist and medical oncologist focused on developing transformational treatments for patients with hematological malignancies. She has developed and conducted several studies that led to Venetoclax Breakthrough Therapy and Orphan Drug Designations in AML and global approvals in CLL and AML indications. Prior to joining the VENCLEXTA clinical development team in 2013, Dr. Potluri was a faculty member at the University of Illinois and at the Advocate Health Centers, where she had been involved in national co-operative oncology trials in hematologic malignancies and was the director of the cancer committee. Dr. Potluri completed her M.D. at Nagarjuna University, India, and fellowship training in Hematology and Medical

Oncology at the Medical College of Wisconsin. She now continues leading teams at AbbVie investigating VENCLEXTA and other agents as potential treatments across multiple tumor types.

**Lori Ehrlich, MD, PhD, U.S. Food and Drug Administration**



Dr. Lori Ehrlich is a pediatric hematologist/oncologist serving as a clinical team leader in the FDA's Division of Hematologic Malignancies I in the Office of Oncologic Diseases. She joined the FDA in 2014 and reviews drugs for malignant hematology indications with a focus on acute leukemias and pediatric drug development. Dr. Ehrlich completed her residency and fellowship training as a pediatric hematologist-oncologist at the Children's Hospital of Philadelphia. She received her medical degree and doctorate from the University of Pittsburgh School of Medicine.

**Kelly Norsworthy, MD, U.S. Food and Drug Administration**



Dr. Norsworthy is a medical oncologist and hematologist who serves as Scientific Liaison for AML in the Division of Hematologic Malignancies I (DHMI) at the FDA. She is a Clinical Team Leader on one of the leukemia/MDS/CML teams in DHMI. Her interests include development of novel therapeutics for AML, MDS, and myeloproliferative neoplasms and assessment of clinical trial endpoints for AML and MDS. Dr. Norsworthy attended the University of Maryland School of Medicine where she received her M.D., completed residency training, and served as Chief Resident of the Internal Medicine training program. She completed her fellowship in Hematology and Medical Oncology at Johns Hopkins Hospital. Dr. Norsworthy remains clinically active, practicing inpatient leukemia part-time as an Adjunct Assistant Professor of Oncology at Johns Hopkins Hospital.